CDKN1B and melanoma: For example, loss of nuclear CDKN1B expression is correlated with a worse 5-year survival of primary melanoma patients in Kaplan–Meier analysis, but gain of cytoplasmic CDKN1B was associated with a poor 5-year survival of metastatic melanoma patients.